COMMUNIQUÉS West-GlobeNewswire

Diversicare announces retirement of Chief Executive Officer and appointment of Jay McKnight as new Chief Executive Officer

09/07/2018 - 14:30

BRENTWOOD, Tenn., July 09, 2018 (GLOBE NEWSWIRE) -- Diversicare Healthcare Services, Inc. (NASDAQ:DVCR) today announced that Kelly J. Gill has retired as Chief Executive Officer of Diversicare effective July 6, 2018. [...]

Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

09/07/2018 - 14:30

All Four Proposals Approved by Shareholders SAN DIEGO, July 09, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that at its Extraordinary General [...]

Transactions under Novozymes’ stock buyback program

09/07/2018 - 14:13

Please read the full announcement in the attached PDF Attachment 2018_42_Stock_Buybackprogram_EN

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2018 After Market Close on July 16, 2018

09/07/2018 - 14:05

TUSTIN, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]

Allscripts to release second-quarter 2018 financial results August 2

09/07/2018 - 14:01

CHICAGO, July 09, 2018 (GLOBE NEWSWIRE) -- Allscripts Healthcare Solutions, Inc . (Nasdaq:MDRX) will report its financial results for the three months ended June 30, 2018, after the close of stock market hours on [...]

Codexis Doses First Subjects in Phase 1a Trial of CDX-6114

09/07/2018 - 14:00

Triggers $4 million milestone payment under strategic collaboration with Nestlé Health Science REDWOOD CITY, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, [...]

Teneobio Announces Research Collaboration with Janssen to Develop Multispecific Antibodies for Oncology

09/07/2018 - 14:00

MENLO PARK, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company, announced today the initiation of a research collaboration and licensing agreement [...]

VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit

09/07/2018 - 14:00

CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today [...]

The American Health Council Welcomes Daniel Lichtstein, MD to Board of Physicians

09/07/2018 - 14:00

NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- The American Health Council welcomed Daniel Lichtstein, MD to its Board of Physicians for his outstanding contributions to the medical field. Currently serving as the Regional [...]

Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177

09/07/2018 - 14:00

Strategic Partnership Supports Commercialization Beyond Ongoing Phase 3 VISION Trial of 177Lu-PSMA-617 WEST LAFAYETTE, Ind. and GARCHING, Germany, July 09, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), and ITM [...]

Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study

09/07/2018 - 14:00

Information and data from study will advance understanding of medical history and medical events in people with PWS People living with PWS ages 5 and older and their caregivers are encouraged to participate BOSTON, July [...]

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma

09/07/2018 - 14:00

MADISON, Wis., July 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of [...]

Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands

09/07/2018 - 14:00

NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at [...]

Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate

09/07/2018 - 14:00

LOS ALTOS, Calif. and LOS ANGELES, July 09, 2018 (GLOBE NEWSWIRE) -- Retrotope and collaborators led by Dr. Marie-Francoise Chesselet, the Charles H. Markham Professor of Neurology, and Interim Chair of the Department [...]

Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters

09/07/2018 - 14:00

SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced two new additions to [...]

Biotricity Provides Fiscal 2018 First Quarter Updates for Shareholders

09/07/2018 - 14:00

With Bioflux FDA clearance and initial revenue, Biotricity focuses on sales growth and the development of its future products REDWOOD CITY, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a [...]

Eyenovia Appoints Michael Rowe as Vice President of Marketing Ahead of Initiation of Multiple Phase III Programs

09/07/2018 - 13:30

NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to [...]

Nephros Announces Preliminary Financial Results for Second Quarter 2018

09/07/2018 - 13:30

Anticipates 57% Year-over-Year Revenue Growth; Establishes Specialty Renal Products Subsidiary SOUTH ORANGE, NJ, July 09, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company [...]

Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994

09/07/2018 - 13:30

Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses Data support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to initiate around year- [...]